Clinical Trial Update: ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

This Phase I trial evaluated single ascending dose and multiple dose regimens of ALX-0171 in healthy male volunteers and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• ALX-0171

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: RSV Infection | Phase 1 | Status: COMPLETED